We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
51
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$3.41M 0.22%
442
-3,946
-90% -$284K
SAGE
52
CALL
DELISTED
Sage Therapeutics
SAGE
$3.38M 0.22%
424
+136
+47% +$9.83K
INSM icon
53
PUT
Insmed
INSM
$22.9B
$3.26M 0.21%
1,899
-1,162
-38% -$19.8K
KITE
54
DELISTED
Kite Pharma, Inc.
KITE
$3.25M 0.21%
+31,384
New +$2.56M
PCRX icon
55
CALL
Pacira BioSciences
PCRX
$1.06B
$3.24M 0.21%
+679
New +$31.5K
PCRX icon
56
PUT
Pacira BioSciences
PCRX
$1.06B
$3.23M 0.21%
+678
New +$31.5K
GILD icon
57
CALL
Gilead Sciences
GILD
$166B
$3.21M 0.21%
454
-7,832
-95% -$521K
MBAI
58
Check-Cap
MBAI
$8.04M
$2.72M 0.18%
5,912
+4,871
+468% +$2.37M
FOLD
59
PUT
DELISTED
Amicus Therapeutics
FOLD
$2.7M 0.18%
2,682
+441
+20% +$3.55K
WVE icon
60
Wave Life Sciences
WVE
$1.13B
$2.64M 0.17%
+141,700
New +$3.05M
ZGNX
61
CALL
DELISTED
Zogenix, Inc.
ZGNX
$2.52M 0.16%
1,735
+919
+113% +$11.6K
BLRX
62
BioLineRX
BLRX
$12.3M
$2.51M 0.16%
4,915
-321
-6% -$165K
ASXC
63
DELISTED
Asensus Surgical, Inc.
ASXC
$2.46M 0.16%
+266,103
New +$2.53M
OTLK icon
64
Outlook Therapeutics
OTLK
$184M
$2.37M 0.16%
14,786
+796
+6% +$225K
SGEN
65
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$2.27M 0.15%
438
+196
+81% +$12.5K
KDMN
66
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.11M 0.14%
+542,869
New +$1.54M
ARRY
67
PUT
DELISTED
Array Biopharma Inc
ARRY
$2.09M 0.14%
2,500
– –
IMMP
68
Immutep
IMMP
$56M
$1.99M 0.13%
+962,835
New +$2.33M
OCGN icon
69
Ocugen
OCGN
$423M
$1.95M 0.13%
18,073
-184
-1% -$18.8K
SRRA
70
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.95M 0.13%
41,562
-2,095
-5% -$107K
GBT
71
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.83M 0.12%
670
+265
+65% +$7.88K
MBOT icon
72
Microbot Medical
MBOT
$115M
$1.82M 0.12%
+85,690
New +$4.73M
CRMD icon
73
CorMedix
CRMD
$575M
$1.82M 0.12%
+848,783
New +$2.9M
PTCT icon
74
CALL
PTC Therapeutics
PTCT
$6.3B
$1.79M 0.12%
977
+824
+539% +$11.1K
PSTV icon
75
Plus Therapeutics
PSTV
$25.3M
$1.79M 0.12%
9
+2
+29% +$404K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.